Diez aspectos clave sobre el uso de la vasopresina en el paciente crítico

IF 2.7 4区 医学 Q2 CRITICAL CARE MEDICINE Medicina Intensiva Pub Date : 2024-09-25 DOI:10.1016/j.medin.2024.07.008
Ricard Ferrer , Pedro Castro , Carol Lorencio , Josman Monclou , Pilar Marcos-Neira , Ana Ochagavía , Juan Carlos Ruíz-Rodríguez , Josep Trenado , Christian Villavicencio , Juan Carlos Yébenes , Lluís Zapata , en nombre del Grupo de trabajo de sepsis de la SOCMIC
{"title":"Diez aspectos clave sobre el uso de la vasopresina en el paciente crítico","authors":"Ricard Ferrer ,&nbsp;Pedro Castro ,&nbsp;Carol Lorencio ,&nbsp;Josman Monclou ,&nbsp;Pilar Marcos-Neira ,&nbsp;Ana Ochagavía ,&nbsp;Juan Carlos Ruíz-Rodríguez ,&nbsp;Josep Trenado ,&nbsp;Christian Villavicencio ,&nbsp;Juan Carlos Yébenes ,&nbsp;Lluís Zapata ,&nbsp;en nombre del Grupo de trabajo de sepsis de la SOCMIC","doi":"10.1016/j.medin.2024.07.008","DOIUrl":null,"url":null,"abstract":"<div><div>The most used vasopressors in critically ill patients are exogenous catecholamines, mainly norepinephrine. Their use can be associated with serious adverse events and even increased mortality, especially if administered at high doses. In recent years, the addition of vasopressin has been proposed to counteract the deleterious effects of high doses of catecholamines (decatecholaminization) with the intention of improving the prognosis of these patients. Currently, vasopressin has two main indications: septic shock and vasoplegic shock in the postoperative period of cardiac surgery. In septic shock, current evidence favors its early initiation before reaching high doses of norepinephrine. In the postoperative period of cardiac surgery, the different benefits of the use of vasopressin have been studied, especially in patients with atrial fibrillation and pulmonary hypertension. When used properly, vasopressin is a safe an effective drug for the indications described above.</div></div>","PeriodicalId":49268,"journal":{"name":"Medicina Intensiva","volume":"48 12","pages":"Pages 704-713"},"PeriodicalIF":2.7000,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina Intensiva","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0210569124003097","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

The most used vasopressors in critically ill patients are exogenous catecholamines, mainly norepinephrine. Their use can be associated with serious adverse events and even increased mortality, especially if administered at high doses. In recent years, the addition of vasopressin has been proposed to counteract the deleterious effects of high doses of catecholamines (decatecholaminization) with the intention of improving the prognosis of these patients. Currently, vasopressin has two main indications: septic shock and vasoplegic shock in the postoperative period of cardiac surgery. In septic shock, current evidence favors its early initiation before reaching high doses of norepinephrine. In the postoperative period of cardiac surgery, the different benefits of the use of vasopressin have been studied, especially in patients with atrial fibrillation and pulmonary hypertension. When used properly, vasopressin is a safe an effective drug for the indications described above.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
重症患者使用血管加压素的十大关键问题
重症患者最常用的血管加压药是外源性儿茶酚胺,主要是去甲肾上腺素。使用这些药物可能会导致严重的不良反应,甚至增加死亡率,尤其是在大剂量使用的情况下。近年来,有人提出添加血管加压素来抵消大剂量儿茶酚胺的有害影响(去甲肾上腺素化),以期改善这些患者的预后。目前,血管加压素有两个主要适应症:脓毒性休克和心脏手术术后的血管性休克。对于脓毒性休克,目前的证据支持在使用大剂量去甲肾上腺素之前尽早使用血管加压素。在心脏手术术后,使用血管加压素的不同益处已得到研究,尤其是在心房颤动和肺动脉高压患者中。如果使用得当,血管加压素在上述适应症中是一种安全有效的药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Medicina Intensiva
Medicina Intensiva CRITICAL CARE MEDICINE-
CiteScore
2.70
自引率
20.00%
发文量
146
审稿时长
33 days
期刊介绍: Medicina Intensiva is the journal of the Spanish Society of Intensive Care Medicine and Coronary Units (SEMICYUC) and of Pan American and Iberian Federation of Societies of Intensive and Critical Care Medicine. Medicina Intensiva has become the reference publication in Spanish in its field. The journal mainly publishes Original Articles, Reviews, Clinical Notes, Consensus Documents, Images, and other information relevant to the specialty. All works go through a rigorous selection process. The journal accepts submissions of articles in English and in Spanish languages. The journal follows the publication requirements of the International Committee of Medical Journal Editors (ICMJE) and the Committee on Publication Ethics (COPE).
期刊最新文献
Nutrithorax: an uncommon differential diagnosis of the plankton sign Selective decontamination of the digestive tract in a burns unit reduces the incidence of hospital-acquired infections: A retrospective before-and-after cohort study Implications of opioid-sparing medications in critically ill patients: A scoping review Stress relaxation, another cause of “Pseudo auto-PEEP”? In-hospital cardiac arrest simulation program in a cardiopulmonary critical care unit: A pilot experience
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1